<?xml version="1.0" encoding="UTF-8"?>
<p id="para0007">The European Union (EU) is showing its capacity to coordinate responses at several key levels. The EU's centre for Disease Prevention and Control (ECDC) is an important resource for information about the virus 
 <xref rid="bib0002" ref-type="bibr">[2]</xref>. The EU is also coordinating member states in consortia aimed at commissioning essential medical supplies. The EU regulator, the European Medicines Agency, is working with other regulators, including the US Food and Drugs Administration, to support research and development for new treatments, from vaccines for disease prevention to new or repurposed medicines for use during active SARS-COVID-19 disease. Amongst over 100 candidate treatments for COVID-19, the following currently authorised medicines are already undergoing clinical trials of their safety and effectiveness: the anti-HIV medicines lopinavir/ritonavir, the investigational anti-viral medicine remdesivir, chloroquine and hydroxychloroquine (authorised as anti-malarials and as anti-inflammatory treatments for autoimmune diseases e.g. rheumatoid arthritis), interferons and immune-modulating monoclonal antibodies 
 <xref rid="bib0010" ref-type="bibr">[10]</xref>. Several vaccines are already in phase I clinical trials in healthy volunteers 
 <xref rid="bib0010" ref-type="bibr">[10]</xref>. However, based on previous experience of vaccine development, even the new GSK-Sanofi vaccine partnership 
 <xref rid="bib0011" ref-type="bibr">[11]</xref> estimates that 12â€“18 months may be needed to provide adequate supplies of effective vaccines for the EU region alone.
</p>
